Vitality Watch

Dossier pubmed preclinical 26-aug-2026
Animal model, organoid, or cell-culture result — not yet human

Triple-pathway synergistic senolysis via AKAP1 silencing and calcium overload: An aptamer-functionalized DNAzyme nanoplatform for anti-pulmonary fibrosis research.

Key claim: An L1CAM-aptamer DNAzyme nanoplatform that silences AKAP1 and induces calcium overload selectively clears senescent alveolar type II cells and attenuates bleomycin-induced pulmonary fibrosis in mice without overt toxicity.

Abstract

Idiopathic pulmonary fibrosis (IPF) lacks therapies that reverse disease progression, partly due to persistent senescent alveolar epithelial type II cells (SAEC II). We report a synergistic senolytic strategy combining mitochondrial calcium overload with AKAP1 silencing. An acid-responsive nanoplatform (CCMD@Lipo-Apt) comprising a CaCOcore co-loaded with curcumin (CUR), Mn, and an AKAP1-targeting DNAzyme, enveloped by an L1CAM aptamer-modified lipid bilayer, enables SAEC II-specific homing. Upon lysosomal acidification, CaCOdegrades to release Ca, CUR (mobilizing ER Ca), Mn, and the DNAzyme. Mnsimultaneously activates DNAzyme to knockdown AKAP1 (sensitizing mitochondria to calcium overload) and directly activates caspase-8. This triple mechanism collapses mitochondrial membrane potential and triggers robust apoptosis exclusively in SAEC II. In a bleomycin-induced mouse model, CCMD@Lipo-Apt clears SAEC II, attenuates fibrosis, and restores lung function without overt toxicity. This work establishes a synthetic-lethal axis for targeted IPF therapy.

Why this matters

The finding operationalizes a cell-surface-targeted senolytic strategy (L1CAM aptamer) coupled to a mechanistically novel kill switch — AKAP1 knockdown plus mitochondrial calcium overload — rather than repurposing D+Q, expanding the senolytic modality space beyond small-molecule BCL-2/tyrosine-kinase inhibition. Framed as an IPF therapeutic rather than a healthspan intervention, it stays inside the recurring pattern of bleomycin-mouse senolysis papers that have not yet translated to human fibrotic lung disease. It also implicitly ties senescent-cell vulnerability to mitochondrial Ca²⁺ handling, a node already surfacing in MERCS and mitochondrial-dysfunction pages.

Source

Link

Briefing card

Triple-pathway synergistic senolysis via AKAP1 silencing and calcium overload: An aptamer-functionalized DNAzyme nanoplatform for anti-pulmonary fibrosis research.
Stage: preclinical · pubmed · 26-aug-2026

An L1CAM-aptamer DNAzyme nanoplatform that silences AKAP1 and induces calcium overload selectively clears senescent alveolar type II cells and attenuates bleomycin-induced pulmonary fibrosis in mice without overt toxicity.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.colsurfb.2026.116114

build build 880 · 2bcef25 · 2026-11-18